Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

MarketScreener Homepage  >  Equities  >  Xetra  >  Bayer AG    BAYN   DE000BAY0017

BAYER AG

(BAYN)
  Report
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
News SummaryMost relevantAll newsPress ReleasesOfficial PublicationsSector newsMarketScreener StrategiesAnalyst Recommendations

Bayer : Aims at Carbon Neutrality by 2030

share with twitter share with LinkedIn share with facebook
share via e-mail
0
12/10/2019 | 03:41am EST

By Kim Richters

Germany's Bayer AG (BAYN.XE) said Tuesday that it plans to become carbon neutral in its operations by 2030, as part of a set of sustainability measures.

The pharmaceutical and chemical giant said it aims to reach this target by implementing energy-efficiency standards, using renewable electricity and offsetting remaining emissions through carbon capture.

"Bayer is striving for absolute emission reduction along the entire value chain by engaging with suppliers and customers, as well as in the company's logistics and packaging," it said.

Bayer will report and review its sustainability targets in the same way as it does its financial targets and include them into decision making and management compensation, the company said.

An independent sustainability council with external experts will oversee the company's efforts, it said.

Additionally, Bayer announced a set of health and nutrition access aims. Among other things, the company said it will support smallholder farmers in low-and-middle income countries and it plans to provide millions of women in those countries with access to family-planning measures such as contraceptives.

Write to Kim Richters at kim.richters@wsj.com

share with twitter share with LinkedIn share with facebook
share via e-mail
0
Latest news on BAYER AG
09:57aBAYER : confirms leading international position as a sustainable company taking ..
AQ
01/20BAYER AKTIENGESELLSCHAFT : Release according to Article 40, Section 1 of the WpH..
EQ
01/20Japan, U.S. lead survey's corporate climate change action 'A List'
RE
01/18Drugmakers slash prices to be eligible for China's bulk-buy program
RE
01/17Bayer could be close to Roundup settlement, mediator says
RE
01/17EUROPE : European shares touch all-time peak on cross-Atlantic trade optimism
RE
01/17A flurry of news in the global auto industry
01/16BAYER AKTIENGESELLSCHAFT : Release according to Article 40, Section 1 of the WpH..
EQ
01/16BAYER : and WuXi Biologics enter into an agreement on a Leverkusen drug product ..
PU
01/15China's 'market condition' caveat on U.S. ag purchases adds to trade deal dou..
RE
More news
Financials (EUR)
Sales 2019 43 974 M
EBIT 2019 7 853 M
Net income 2019 3 106 M
Debt 2019 35 649 M
Yield 2019 3,77%
P/E ratio 2019 24,5x
P/E ratio 2020 16,0x
EV / Sales2019 2,50x
EV / Sales2020 2,29x
Capitalization 74 173 M
Chart BAYER AG
Duration : Period :
Bayer AG Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends BAYER AG
Short TermMid-TermLong Term
TrendsBullishBullishBullish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 28
Average target price 81,28  €
Last Close Price 75,50  €
Spread / Highest target 62,9%
Spread / Average Target 7,66%
Spread / Lowest Target -48,7%
EPS Revisions
Managers
NameTitle
Werner Baumann Chairman-Management Board
Werner Wenning Chairman-Supervisory Board
Wolfgang U. Nickl Chief Financial Officer
Katharina Jansen Head-Science & Research
Florian Schwalbach Head-Information Technology & Business Services
Sector and Competitors
1st jan.Capitalization (M$)
BAYER AG3.69%82 204
JOHNSON & JOHNSON2.26%392 596
ROCHE HOLDING AG4.44%289 068
MERCK AND COMPANY0.02%231 608
PFIZER3.39%224 187
NOVARTIS0.96%216 654